Skip to main content

Table 2 Parameters during the follow-up in the TDF-reducing therapy group (n = 364). Dual therapy (DT) Alanine transaminase (ALT) Aspartate transaminase (AST) High-density lipoprotein (HDL) Low-density lipoprotein (HDL) Creatinine clearance (CCr) platelet-to-lymphocyte ratio (PLR) neutrophil-to-lymphocyte ratio (NLR)

From: Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015

Parameters 12 months before
Mean (SD)
6 months before
Mean (SD)
Swicht to DT
Mean (SD)
6 months after switch
Mean (SD)
12 months after switch
Mean (SD)
From 12 months
before to switcha
Coef. (CI 95%)
p-value From switch to 12 months aftera
Coef. (CI 95%)
p-value
CD4 cell count, cell/mm3 611.1 (302.8) 630.5 (300.5) 631.6 (295.6) 659.3 (295.9) 699.2 (296.3) 1.9 (0.3,3.5) 0.023 6.8 (4.9,8.8) < 0.001
CD8 cell count, cell/mm3 900.1 (423.6) 910.2 (439.7) 872.3 (438.6) 928.4 (475.8) 919.2 (474.2) −1.8 (− 4.9,1.4) 0.272 4.2 (1.2, 7.6) 0.007
ALT (U/l) 40.8 (46.8) 38.4 (33.9) 37.2 (30.4) 38.4 (44.6) 36.6 (35.6) −0.3 (− 0.7,0.0) 0.045 − 0.0 (− 0.1,0.4) 0.890
AST (U/l) 33.6 (37.4) 30.3 (22.8) 30.3 (24.3) 29 (29.4) 30.2 (26.6) −0.3 (− 0.6–0.0) 0.028 −0.0 (− 0.3,0.2) 0.760
Total Cholesterol (mg/dl) 184.9 (40.6) 186.9 (40.6) 186 (41.4) 208.4 (45.9) 199.7 (45.5) 0.1 (−0.2,0.4) 0.601 1.5 (1.1,1.9) < 0.001
HDL Cholesterol (mg/dl) 44.7 (14.8) 45.9 (16.4) 46 (15.9) 49.6 (15.4) 48.9 (15.9) 0.2 (0.0,0.3) 0.009 0.3 (0.2,0.5) < 0.001
LDL Cholesterol (mg/dl) 111.9 (35) 113.1 (34.5) 114.3 (34) 125.1 (37.2) 120 (38.2) −0.1 (−0.2, 0.5) 0.534 0.7 (0.2, 1.1) 0.005
Triglycerides (mg/dl) 157.1 (90.9) 160.5 (85.1) 155.7 (105.2) 174.3 (125.3) 176.3 (141.2) −0.2 (−1.2,0.7) 0.629 1.3 (0.3,2.3) 0.009
CCr (ml/min) 92.1 (25.2) 91.1 (28.5) 88.6 (30.2) 93.2 (28.6) 95.8 (29.7) −0.4 (−0.5, − 0.2) < 0.001 0.5 (0.3,0.6) < 0.001
Lymphocyte, 103/μL 2087 (789) 2100 (767) 2062 (791) 2202 (868) 2236 (867) −3.3 (−8.0, 3.3) 0.259 16.9 (11.2,22.6) < 0.001
Neutrophils, 103/μL 4230 (5825) 3435 (1386) 3422 (1344) 3444 (1463) 3560 (1610) −65.4 (− 127.4–3.4) 0.039 20.3 (− 1.8, 42.4) 0.072
Platelets, 103/μL 216,359 (76022) 216,525 (73144) 218,494 (72903) 214,413 (69168) 214,286 (69895) −10.9 (− 394.4, 372.96) 0.955 − 420.4 (− 810.2, − 30.5) 0.035
NLR 1.9 (0.9) 1.9 (0.9) 2 (1.1) 1.9 (1.2) 1.9 (0.9) 0.1 (0.0,0.2) 0.067 0.0 (−0.0, 0.0) 0.355
PLR 114.2 (51.5) 113.4 (51.6) 118.7 (59.5) 109.4 (52.8) 105.0 (46.0) 0.3 (−0.1, 0.8) 0.110 −1.2 (−1.6,-0.7) < 0.001
CD4/CD8 0.79 (0.48) 0.8 (0.5) 0.84 (0.47) 0.81 (0.42) 0.88 (0.43) 0.004 (0.001,0.008) 0.008 0.003 (0.001,0.005) 0.002
  1. In the analysis we performed random effects mixed models in order to evaluate the role of time (in months) on the changes in biochemical parameters
  2. aResults remained unchanged when sensitivity analysis by multiple imputation for missing data was performed